Tobraz 100 mg (Tobramycin)
Tobramycin 50mg
Injections · Prescription medication
Daewoong Pharmaceutical Co., Ltd.
MFDS item code 199300663 · Notified 1993.02.01 · Insurance code 641602441
Treatment of bacterial infections (e.g., pneumonia and sepsis) and eye infections (e.g., conjunctivitis and keratitis)
The injection is effective against various bacteria such as Pseudomonas, Proteus, Escherichia coli, and Klebsiella, and is used for the treatment of infections like meningitis and pneumonia, which are central nervous system infections, as well as gastrointestinal infections such as peritonitis, skin and soft tissue infections, postoperative wound infections, osteomyelitis, sepsis, and severe pyelonephritis or recurrent cystitis. The eye drops and ointment are effective against various bacterial strains related to eye infections such as Staphylococcus aureus, Streptococcus, and Pseudomonas, and are used to treat blepharitis, dacryocystitis, stye, conjunctivitis, keratitis, and corneal ulcers. Thus, these medicines can broadly respond to various bacterial infections, helping to improve symptoms and treat diseases.
(Injection) 1. Adults: For severe infections, administer 3mg (potency) of tobramycin per Kg of body weight per day in 3 divided doses by intravenous or intramuscular injection. For life-threatening infections, up to 5mg (potency) per Kg of body weight per day may be administered in 3~4 divided doses. When symptoms improve, reduce the dose to 3mg (potency) per Kg of body weight per day. Do not administer more than 5mg (potency) per Kg of body weight per day without measuring serum concentrations. Treatment usually lasts 7~10 days. The duration may be extended depending on the severity of the infection; in such cases, monitor renal, vestibular, and auditory function (neurotoxicity is more likely to occur when treatment lasts longer than 10 days). 3. Patients with renal impairment Measure serum concentrations of this medicine if possible. Administer an initial dose of 1mg (potency) per Kg of body weight, then reduce subsequent doses or extend the dosing interval starting with the second dose. If serum concentrations of this medicine cannot be measured directly, calculate the dose based on creatinine clearance or serum creatinine concentration and adjust it while monitoring the patient's condition. However, these methods should not be used during dialysis. 1) Dose reduction (8-hour dosing interval): If creatinine clearance is 70mL/min or less, or if serum creatinine concentration is known, calculate the dose by multiplying the dose for a patient with normal renal function by the corresponding % value in <Table 1>. If the patient's steady-state serum creatinine concentration is known, an approximate dose can be calculated by dividing the dose for a patient with normal renal function by the serum creatinine concentration. 2) Extended dosing interval (same dose as for patients with normal renal function): If the patient's creatinine clearance cannot be measured and the patient's condition is stable, administer at intervals calculated by multiplying the serum creatinine concentration by 6. Adjust the dose appropriately according to age and symptoms. <Preparation of this medicine> For intramuscular injection, dissolve in 1.5mL of normal saline for injection or water for injection. For intravenous injection in adults, dilute the dose in 50~100mL of normal saline for injection or 5% dextrose injection and administer by intravenous drip over 20~60 minutes. Avoid intravenous drip infusion over less than 20 minutes, as serum tobramycin concentrations may exceed 12mg/mL. It is preferable not to mix this medicine with other drugs. (Ophthalmic solution) For mild to moderate infections, instill 1~2 drops into the infected area every 4 hours. For severe infections, instill 2 drops every hour until symptoms improve, then gradually reduce and discontinue. Adjust the dose appropriately according to age and symptoms. (Ophthalmic ointment) For mild to moderate infections, apply approximately 1cm to the infected area 2~3 times daily. For severe infections, apply 1cm to the infected area every 3~4 hours until symptoms improve, then gradually reduce and discontinue. Adjust the dose appropriately according to age and symptoms.
Children: Administer 5mg (potency) per Kg of body weight per day in 3~4 divided doses by intravenous or intramuscular injection. Neonates (less than 1 week old): Administer 4mg (potency) per Kg of body weight per day in divided doses every 12 hours. For children, reduce the volume of diluent proportionally.
This medication is an aminoglycoside antibiotic and should not be administered to certain patients. For example, it should not be used in patients who are allergic to this drug or similar antibiotics, patients with ear diseases, severe kidney dysfunction, pregnant or breastfeeding women, patients with muscle diseases, patients with bronchial asthma, and patients with 8th cranial nerve disorders. Additionally, patients with a family history of hearing loss or kidney dysfunction, patients with weak kidney or liver functions, premature infants or newborns, elderly patients, and those with poor nutritional status should use this medication with extra caution. Due to the sodium bisulfite included in this medication, allergic reactions or asthmatic attacks may occur, so care is needed. While it is rare, using this drug may lead to severe shock, gastrointestinal symptoms, blood abnormalities, central nervous system disorders, liver and kidney disorders, skin reactions, hypersensitivity reactions, vitamin deficiency symptoms, pain at the injection site, etc., so if any symptoms occur, healthcare personnel should be notified immediately. This medication should be used for the necessary duration following a susceptibility test to prevent the development of resistant bacteria, and it is advisable to carry out allergy reaction tests before administration. Furthermore, due to the risk of hearing loss and kidney damage, it is best not to exceed 10 days of administration, and when used for an extended period, serum drug levels and hearing tests should be checked regularly. This medication may interact with other drugs, especially those that affect the kidneys such as blood substitutes, anesthetics, muscle relaxants, anticoagulants, diuretics, etc., so caution is needed. During pregnancy, it may pose risks to the fetus, so it should only be used when necessary, and breastfeeding should be suspended during administration. Newborns or low-birth-weight infants have immature kidney function, thus requiring special caution, such as extending the dosing interval, while elderly patients have a higher risk of side effects due to declining kidney function, so they should be carefully monitored during administration. In case of overdose, kidney damage, hearing and vestibular dysfunction, respiratory paralysis, etc., can occur, and appropriate treatment should be sought immediately at a medical institution. Additionally, this medication should not be mixed with beta-lactam antibiotics and should be administered via other routes. Resistance has been reported for this medication against specific bacteria, therefore, it is vital to confirm the effectiveness of this drug through proper testing when treating infections.
Shock, nausea, vomiting, loss of appetite, stomatitis, diarrhea, anemia, leukopenia, leukocytosis, granulocytosis, eosinophilia, thrombocytopenia, dizziness, tinnitus, hearing loss, otalgia, a feeling of ear blockage, lip numbness, limb paralysis, drowsiness, headache, somnolence, mental confusion, localized loss, heaviness, nonsensical speech, loss of directional sense, increased ALT, increased AST, increased serum LDH, increased bilirubin, liver dysfunction, jaundice, acute renal failure, edema, elevated BUN, elevated NPN, elevated serum creatinine, oliguria, proteinuria, hematuria, electrolyte imbalance, exfoliative dermatitis, toxic epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome, rash, urticaria, itching, erythema, fever, symptoms of vitamin K deficiency, hypoprothrombinemia, tendency to bleed, symptoms of vitamin B complex deficiency, glossitis, neuritis, pain at the injection site, induration at the injection site, inflammation at the injection site, phlebitis, excessive growth of non-susceptible bacteria, kidney damage, hearing impairment, vestibular disorders, symptoms of neuromuscular blockade, respiratory paralysis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container that does not come into contact with air and should be kept away from direct sunlight and at room temperature. By storing it at appropriate temperatures, the effectiveness and safety of the drug can be maintained.
A vial injection of colorless and transparent liquid
1 vial (2 mL) x 10
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Tobramycin 50mg
Injections · Prescription medication
Daewoong Pharmaceutical Co., Ltd.
Tobramycin 40mg
Injections · Prescription medication
(Co., Ltd.) Daewoong Pharmaceutical
Tobramycin 300mg
Eye drops · Prescription medication
Daewoong Pharmaceutical Co., Ltd.
Tobramycin 40mg
Prescription medication
Alvogen Korea Co., Ltd.
Tobramycin 3mg
Eye drops · Prescription medication
Samchundang Pharmaceutical Co., Ltd.
Tobramycin
Prescription medication
You & Life Science Co., Ltd.
Tobramycin 3mg
Eye drops · Prescription medication
Hanlim Pharmaceutical Co., Ltd.
Tobramycin
Prescription medication
Anguk Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.